Welgene BiotechLtd Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yi Xing Lin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Is Welgene Biotech Co.,Ltd.'s (GTSM:6661) 4.7% Dividend Sustainable?

Mar 19

Are Welgene BiotechLtd's (GTSM:6661) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 10

Welgene Biotech Co.,Ltd.'s (GTSM:6661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 13

Know This Before Buying Welgene Biotech Co.,Ltd. (GTSM:6661) For Its Dividend

Dec 10

CEO

Yi Xing Lin

no data

Welgene BiotechLtd Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Welgene Biotech Co.,Ltd., Annual General Meeting, May 30, 2024

Welgene Biotech Co.,Ltd., Annual General Meeting, May 17, 2022

Welgene Biotech Co.,Ltd., Annual General Meeting, May 25, 2021

Recent updates

Full year 2023 earnings released: NT$0.11 loss per share (vs NT$0.41 profit in FY 2022)

Welgene Biotech Co.,Ltd., Annual General Meeting, May 30, 2024

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.25 (vs NT$0.54 in 2Q 2022)

Upcoming dividend of NT$0.18 per share at 2.1% yield

Full year 2022 earnings released: EPS: NT$0.41 (vs NT$0.59 in FY 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: NT$0.22 loss per share (vs NT$0.25 loss in 1Q 2021)

Upcoming dividend of NT$0.48 per share

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Welgene Biotech Co.,Ltd., Annual General Meeting, May 17, 2022

Third quarter 2021 earnings released

Upcoming dividend of NT$1.10 per share

First quarter 2021 earnings released: NT$0.25 loss per share (vs NT$0.27 profit in 1Q 2020)

Is Welgene Biotech Co.,Ltd.'s (GTSM:6661) 4.7% Dividend Sustainable?

Full year 2020 earnings released: EPS NT$1.44 (vs NT$1.49 in FY 2019)

Welgene Biotech Co.,Ltd., Annual General Meeting, May 25, 2021

Are Welgene BiotechLtd's (GTSM:6661) Statutory Earnings A Good Reflection Of Its Earnings Potential?

New 90-day low: NT$27.60

Investor sentiment deteriorated over the past week

Welgene Biotech Co.,Ltd.'s (GTSM:6661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

New 90-day low: NT$33.20

Know This Before Buying Welgene Biotech Co.,Ltd. (GTSM:6661) For Its Dividend

Third quarter 2020 earnings released: EPS NT$0.45

New 90-day high - NT$38.40

First half earnings released

CEO

Permanencia